MPD: List measures where strain BALB/cByJ is an outlier

List measures where BALB/cByJ is an outlier

Click on pulldowns below to see BALB/cByJ means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Berndt2:91	Berndt2	ventilator	methacholine	lung tissue dynamic elastance (H₂0 pressure) [cm/mL] airway_elas 35191 saline 1 MCh 3 MCh 10 MCh 30 MCh response index	inbred	29	both	9-12wks	N=9	2010

Brown1:14	Brown1	open field test	(none)	urine puddle count, 5 min test, day 1 [n] urination_d1_OFT 9414	inbred	14	both	10wks	N=13	2004

Brown1:19	Brown1	light-dark box	(none)	urine puddle count [n] urination_LD 9419	inbred	14	both	10wks	N=13	2004

Brown1:32	Brown1	elevated zero maze	(none)	fecal boli count [n] defecation_EZM 9432	inbred	13	both	10wks	N=9	2004

Brown2:57	Brown2	visual water box	(none)	latency to reach cued platform [s] vis_acuit 22557 grating threshold: 0.17 (low) 0.32 0.64 (high) overall mean	inbred	14	both	10-18wks	N=7	2004

Bryant1:35	Bryant1	nociception assay	oxycodone	percentage of maximum possible effect: latency to hind paw lick or jump at 0.625 mg/kg, hot plate, 1 min test [%] max_effect_HP 118071 group: saline oxycodone	inbred	29	both	9-16wks	N=4	2022

CGDpheno1:48	CGDpheno1	lipid profile	(none)	non-esterified free fatty acids (plasma NEFA, FFA) [mEq/L] NEFA 31848	inbred w/CC8	72	both	12wks	N=7	2009

CSNA01:16	CSNA01	operant conditioning chamber	sucrose	variable ratio 2 (VR2), lever press rate, 8 h test [n] VR2rate 60216 day 1 day 2 day 3 across 3 days	HMDP	91	m	7-22wks	N=4	2018

CSNA01:26	CSNA01	operant conditioning chamber	sucrose	variable ratio 5 (VR5), lever press rate, 8 h test [n/s] VR5rate 60226 day 1 day 2 day 3 across 3 days	HMDP	91	m	7-22wks	N=4	2018

Eumorphia7:1	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin M (serum IgM) [µg/mL] IgM 29601	inbred	6	both	9-12wks	N=5	2008

Evsikova1:61	Evsikova1	intake monitoring	(none)	food intake [g] food 24761 daily light dark	inbred	14	both	26wks	N=6	2009

Golani1:13	Golani1	open field test	(none)	diversity of lingering episodes, 30 min test, logit transformed [logit(cm)] DVRS 10913	inbred	8	m	10wks	N=34	2003

Graubert1:17	Graubert1	histopathology	ENU	lung carcinoma frequency rate [score] carcinoma_lung 11617 control ENU	inbred	20	both	13-68wks	N=6	2006

Harrill2:11	Harrill2	metabolic panel	DB289	alanine transaminase (serum ALT) [IU/L] ALT 44111 control DB289 difference	inbred	34	f	6-8wks	N=5	2012

Harrill2:35	Harrill2	biomarker quantification	DB289	urine kidney injury molecule 1 (KIM-1) [pg] urine_KIM1 44135 control DB289 difference	inbred	33	f	6-8wks	N=4	2012

Jax5:13	Jax5	colony observation	(none)	percent females weaned per dam [%] pct_female_dam 31413	inbred	35	f	6-40wks	N=46	2009

Jax5:14	Jax5	colony observation	(none)	female to male ratio per dam, adjusted for biological parameters [ratio] sex_ratio 31414	inbred	35	f	6-40wks	N=38	2009

Jaxpheno2:34	Jaxpheno2	organ weights	(none)	kidney (left) weight, as percentage of body weight [%] pct_kidney_L 22734 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno3:15	Jaxpheno3	metabolic panel	(none)	alanine transaminase (plasma ALT) [IU/L] ALT 22815 age 8wks age 16wks	inbred	11	both		N=16	2006

Loos2:32	Loos2	home cage monitoring	(none)	change in Feeding zone duration: anticipation of phase change, over 3 days of testing feeding_anticipation 54032 dark light	inbred w/CC7	11	m	8-12wks	N=35	2016

Maurer1:1	Maurer1	tail cuff	atenolol, isoproterenol	pulse rate [n/min] pulse 33201 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Metten2:3	Metten2	behavior observation	ethanol	peak handling-induced convulsion (HIC) score [score] peak 19503 control ethanol ethanol normalized to controls	inbred	15	m	8-15wks	N=9	2005

Moy1:1	Moy1	three chamber assay	(none)	time spent in chamber with stranger 1 (a novel mouse), 10 min test [s] DurSTR1_soc 30101	inbred	17	m	6-7wks	N=22	2008

Moy1:3	Moy1	three chamber assay	(none)	time spent in center chamber, 10 min test [s] DurCEN_soc 30103	inbred	17	m	6-7wks	N=22	2008

Moy1:10	Moy1	three chamber assay	(none)	time spent in center chamber, 10 min test [s] DurCEN_nov 30110	inbred	17	m	6-7wks	N=22	2008

Peters1:7	Peters1	complete blood count	(none)	mean RBC corpuscular hemoglobin concentration (MCHC) [g/dL] MCHC 6207	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:8	Peters1	complete blood count	(none)	RBC corpuscular hemoglobin concentration mean (CHCM) [g/dL] CHCM 6208	inbred w/CC7	43	both	10wks	N=12	2001

Peters4:49	Peters4	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctBASO 24349 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:61	Peters4	complete blood count	(none)	hemoglobin (HGB) [g/dL] HGB 24361 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Petkova1:1	Petkova1	immune cell quantification	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 24201 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:16	Petkova1	immune cell quantification	(none)	eosinophil differential (EOS; percentage of total WBC) [%] EOS 24216 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:61	Petkova1	immune cell quantification	(none)	CD8 T cells, central memory, as percentage of total CD8 T cells [%] CD8_mem_central 24261 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:71	Petkova1	immune cell quantification	(none)	CD8 T cells, effector, as percentage of total CD8 T cells [%] CD8_effector 24271 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Project1032:1	Project1032	operant conditioning chamber	(none)	number of infusions earned (intravenous self administration), saline [n] infusions_control 111414 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:21	Project1032	operant conditioning chamber	(none)	number of infusions earned (intravenous self administration) combined, saline [n] infusions_combined_control 111434 days 1-4 days 5-7 days 8-10	HMDP	66	both	9-15wks	N=2	2020

Project1032:27	Project1032	operant conditioning chamber	(none)	percentage of lever presses that are active (intravenous self administration), saline [%] active_pct_control 111440 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:53	Project1032	operant conditioning chamber	(none)	number of active lever presses (during infusions and timeouts) (intravenous self administration), saline [n] active_control 111466 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:79	Project1032	operant conditioning chamber	(none)	number of inactive lever presses (intravenous self administration), saline [n] inactive_control 111492 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=2	2020

Project1032:99	Project1032	operant conditioning chamber	(none)	number of inactive lever presses (intravenous self administration) combined, saline [n] inactive_combined_control 111512 days 1-4 days 5-7 days 8-10	HMDP	66	both	9-15wks	N=2	2020

Project1032:105	Project1032	operant conditioning chamber	(none)	session duration (120 min max) (intravenous self administration), saline [min] session_time_control 111518 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=3	2020

Project1032:125	Project1032	operant conditioning chamber	(none)	session duration (120 min max) (intravenous self administration) combined, saline [min] session_time_combined_control 111538 days 1-4 days 5-7 days 8-10	HMDP	66	both	9-15wks	N=3	2020

Project1149:35	Project1149	None	(none)	max_effect_HP max_effect_HP 118132 SAL OXY	inbred	29	m		N=8	2022

Rusyn2:22	Rusyn2	metabolic panel	trichloroethylene	aspartate transaminase (serum AST), control group [IU/L] AST_ctrl 36122 time: 2h 8h 24h	inbred	16	m	7wks	N=3	2010

Rusyn2:37	Rusyn2	metabolic panel	trichloroethylene	blood urea nitrogen (serum BUN), treated group [mg/dL] BUN_tce 36137 time: 2h 8h 24h	inbred	16	m	7wks	N=3	2010

Rusyn5:25	Rusyn5	metabolite quantification	high-fat diet and ethanol	oxidized liver glutathione (GSSG) [nmol/mg] liver_GSSG 43025 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Schonfeld1:13	Schonfeld1	insulin tolerance	(none)	glucose levels, area under curve, insulin tolerance test (human insulin 0.75 U/kg bw i.p., 5h fast) [AUC] AUC_ITT 32318 0 to 60 min 0 to 120 min	inbred	10	both	9-13wks	N=5	2005

Schonfeld1:18	Schonfeld1	lipid profile	(none)	free fatty acids (plasma FFA) [mol/m³] FFA 32334	inbred	10	both	9-13wks	N=5	2005

Schonfeld1:22	Schonfeld1	lipid profile	(none)	hepatic triglycerides (5h fast) [mg/g] hTG 32348	inbred	11	both	9-13wks	N=6	2005

Schonfeld1:25	Schonfeld1	organ weights	(none)	liver weight [g] LW 32361	inbred	11	both	9-13wks	N=6	2005

Schulz1:4	Schulz1	body weight	(none)	body weight [g] bw 1604	inbred	7	both	12-14wks	N=15	2000

Seburn2:1	Seburn2	grip strength	(none)	grip strength, peak tension over 3 trials [g] grip_strength 24801 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2008

Shimomura2:31	Shimomura2	monitoring system	(none)	free running period in constant light [h] LL_period 52731	inbred w/CC7	38	both	10wks	N=8	2015

Tarantino1:14	Tarantino1	open field test	cocaine	percentage of time resting, 30 min test [%] rest 45931 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Thomsen1:1	Thomsen1	open field test	cocaine	total activity, test 1, 3h test [n] activ_cocaine1 40701 baseline dose mg/kg i.p.: 3 10 18 32 56	inbred	15	both	8-10wks	N=8	2011

Threadgill1:20	Threadgill1	metabolite quantification	acetaminophen	ratio of reduced (GSH) to oxidized (GSSG) glutathione [ratio] GSHratio 19420 control post-Rx 300mg/kg	inbred w/CC7	36	m	8-17wks	N=2	2005

Tomasini1:1	Tomasini1	biomarker quantification	(none)	fibronectin [µg/mL] fibronectin 26101	inbred	25	both	9wks	N=8	2007

Trullas1:3	Trullas1	elevated plus maze	(none)	total number of entries into open and closed arms, elevated maze, 5 min test [n] EM_entries_all 52803	inbred	16	m	6-8wks	N=20	1993

Wahlsten1:51	Wahlsten1	elevated plus maze	(none)	number fecal boli, 5 min trial [n] defecation_EPM 10851	inbred	21	both	9wks	N=9	2003

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:41	Wiltshire4	immune cell quantification	idarubicin	B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Xing1:1	Xing1	ECG	(none)	heart rate [n/min] HR 24901 6mo 12mo 20mo	inbred	29	both		N=7	2008

Xing1:16	Xing1	ECG	(none)	interval RR [ms] RR 24916 6mo 12mo 20mo	inbred	29	both		N=7	2008

Xing1:26	Xing1	ECG	(none)	interval QRS [ms] QRS 24926 6mo 12mo 20mo	inbred	29	both		N=7	2008

Yuan3:6	Yuan3	metabolic panel	(none)	lipase (plasma LIP) [U/L] LIP 24406 6mo 12mo 18mo	inbred	32	both		N=7	2008

List measures where BALB/cByJ is an outlier

Filter Table Results